Presenting Germany's drug pricing rule as a cost-per-QALY rule

Health Care Management Science

Volumn 15, Issue 2, 2012, Pages 103-107

  Gandjour, Afschin ^a  

^a FRANKFURT SCHOOL OF FINANCE AND MANAGEMENT   (Germany)

Author keywords

Drug pricing; Equity; Germany; QALYs

Indexed keywords

PRESCRIPTION DRUG;

ARTICLE; COST; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG COST; DRUG INDUSTRY; ECONOMICS; FEE; GERMANY; HEALTH CARE QUALITY; HUMAN; LEGAL ASPECT; METHODOLOGY; QUALITY ADJUSTED LIFE YEAR; STANDARD; STATISTICS;

COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; DRUG INDUSTRY; FEES, PHARMACEUTICAL; GERMANY; HUMANS; PRESCRIPTION DRUGS; QUALITY OF HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS;

EID: 84859428761     PISSN: 13869620     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10729-011-9186-3     Document Type: Article

References (20)

1. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329): 71-86.
2. Arneson R (1989) Equality and equal opportunity for welfare. Philos Stud 56: 77-93.
3. Barro JR, Huckman RS, Kessler DP (2006) The effects of cardiac specialty hospitals on the cost and quality of medical care. J Health Econ 25(4): 702-21.
4. Brouwer WB, Rutten FF (2010) The efficiency frontier approach to economic evaluation: will it help German policy making? Health Econ 19(10): 1128-31.
5. Caro JJ, Nord E, Siebert U, McGuire A, McGregor M, Henry D, de Pouvourville G, Atella V, Kolominsky-Rabas P (2010) IQWiG methods-a response to two critiques. Health Econ 19(10): 1137-8.
6. Cohen GA (1989) On the currency of egalitarian justice. Ethics 99: 906-944.
7. Cookson R, Hutton J (2003) Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective. Health Policy 63(2): 167-78.
8. Daniels N (1985) Just health care. Cambridge University Press, New York.
9. Daniels N (2008) Just health: Meeting health needs fairly. Cambridge University Press, New York.
10. Dranove D, Kessler D, McClellan M, Satterthwaite M (2003) Is more information better? The effects of "report cards on health care providers". J Polit Econ 111: 555-588.
11. Dworkin R (1981) What is equality? Part 2: equality of resources. Philos Public Aff 10: 283-345.
12. Gandjour A (2011) Germany's decision rule for cost-effectiveness analysis on drugs: a comparative analysis with other decision rules. Appl Health Econ Health Policy 9(2): 65-71.
13. Gandjour A, Gafni A (2011) Expert Rev Pharmacoecon Outcomes Res 2011 11(4): 403-9.
14. Goetghebeur MM, Rindress D (1999) Towards a European consensus on conducting and reporting health economic evaluations-a report from the ISPOR Inaugural European Conference. Value Health 2(4): 281-7.
15. Institute for Quality and Efficiency in Health Care. Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System - Version 1. 0 (in German). October 12, 2009.
16. Institute for Quality and Efficiency in Health Care. Appraisal of IQWiG's Scientific Advisory Board's recommendations regarding draft version 1. 1 (in German). March 16, 2009.
17. Institute for Quality and Efficiency in Health Care (2009) Clopidogrel plus acetylsalicylic acid in acute coronary syndrome (final report). IQWiG Reports - Commission No. A04-01B. Cologne: IQWiG.
18. Nord E (1999) Cost-value analysis in health care: Making sense out of QALYs. Cambridge University Press, Cambridge.
19. Nord E, Pinto JL, Richardson J, Menzel P, Ubel P (1999) Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Econ 8(1): 25-39.
20. Sen AK (1985) Commodities and capabilities. Oxford University Press, Oxford.